Treatment responders exhibited markedly elevated infiltration densities of CD8+ cytotoxic T cells and CD68+ macrophages specifically within the tumor core region, revealing a distinctive spatial immune signature predictive of therapeutic success. The gene discussed is CD8A; the disease is neoplasm.